By Andrew Chung
(Reuters) – The U.S. Supreme Court on Tuesday rejected Merck & Co Inc’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.
The justices declined to take up Merck’s appeal of a lower court’s ruling that overturned the massive damages verdict after finding that Merck’s patent was invalid.
(Reporting by Andrew Chung in New York; Editing by Will Dunham)
